Immunomodulator Global Market Report 2024 by The Business Research Company | Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc,

The immunomodulator market size has grown strongly in recent years. It will grow from $204.37 billion in 2023 to $219.94 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to healthcare infrastructure development, increased awareness among patients, the aging population, increasing incidence of autoimmune diseases, and the introduction of biologic drugs.

The immunomodulator market size is expected to see strong growth in the next few years. It will grow to $297.15 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growing patient preference for non-invasive, regulatory approvals and guidelines, the extent of health insurance coverage for immunomodulatory treatments, the number and progress of immunomodulatory drugs, and government healthcare expenditure. Major trends in the forecast period include advancements in biotechnology and immunotherapy, the number and progress of immunomodulatory drugs in the research and development pipeline, advances in technology, the trend towards personalized medicine, and advancements in immuno-oncology.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=15591&type=smp

Immunomodulator Market Major Segments
The immunomodulator market covered in this report is segmented -

1) By Product Type: Immunosuppressants, Immunostimulants, Other Product Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Oncology, Respiratory, Human Immunodeficiency Virus, Other Applications
4) By End-User: Hospitals, Clinics, Other End Users

Key Driver - Digital Transformation In BFSI Driving The Smart Contract Market's Growth

The rise in chronic diseases is expected to propel the growth of the immunomodulator market. Chronic diseases are long-lasting medical conditions that typically develop gradually over time and persist for extended periods, often lasting for years or even a lifetime. Chronic diseases are becoming more common due to a multitude of interconnected variables, such as an aging population, lifestyle decisions, genetic predispositions, and the accessibility and infrastructure of healthcare. Immunomodulators provide valuable therapeutic options for managing chronic diseases by modulating immune responses, reducing inflammation, preventing organ rejection, enhancing immune surveillance, and improving symptom control. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rise in chronic diseases is driving the growth of the immunomodulator market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=15591&type=smp

Prominent Trend - Innovative Non-Immunosuppressive Immunomodulators Lead Revenue Growth In Major Companies

Companies operating in the immunomodulator market are focused on the development of non-immunosuppressive products to address the growing demand for treatments that offer targeted immune modulation without compromising the body's overall immune function. Non-immunosuppressive refers to treatments or substances that do not suppress or weaken the immune system's response. For instance, in February 2024, Nuvig Therapeutics, Inc., a US-based biotechnology company, initiated early-stage clinical trials for NVG-2089, a next-generation immune modulator. NVG-2089 is a proprietary product designed to treat patients with inflammatory myopathies and severe dermatologic autoimmune diseases. The FDA has granted fast-track designation for NVG-2089's development in bullous pemphigoid. This novel, recombinant, non-immunosuppressive immunomodulator targets type II Fc receptors to trigger an endogenous regulatory mechanism that reduces autoimmune dysregulation. The study's primary objective is to assess the safety and tolerability of NVG-2089, with secondary objectives focusing on pharmacokinetics and pharmacodynamics.

Immunomodulator Market Players
Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Ipsen SA, Kyowa Kirin Co. Ltd., Amicus Therapeutics Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the immunomodulator market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Immunomodulator Market Report Structure
3. Immunomodulator Market Trends And Strategies
4. Immunomodulator Market - Macro Economic Scenario
5. Immunomodulator Market Size And Growth
…..
27. Immunomodulator Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.